Mabwell (Shanghai) Bioscience Co., Ltd. (SHSE: 688062)
Health Care · Biotechnology · CN
CN¥31.17
-8.32% today · -23.6% 1Y
Mabwell (Shanghai) Bioscience Co., Ltd. (SHSE: 688062) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.98B and employs 1,325 people.
Over the last twelve months the share price has lost 23.6%, trading between 25.13 and 63.59.
Tweenvest scores Mabwell (Shanghai) Bioscience Co., Ltd. across four factors: quality 15/100, value 78/100, growth 100/100. Its strongest factor is growth.
688062 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.98B
- Revenue (TTM)
- $108.06M
- P/E
- —
- EPS
- -2.31
- Dividend yield
- —
- Beta (5Y)
- 0.52
- 52-week high
- CN¥63.59
- 52-week low
- CN¥25.13
- Avg volume (3M)
- —
- Shares outstanding
- 445.54M
- Employees
- 1,325
- Next earnings
- —
About Mabwell (Shanghai) Bioscience Co., Ltd.
Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, production, and global commercialization of biological products. The company's comprehensive portfolio addresses a wide spectrum of medical conditions, including autoimmune disorders, various cancers, eye diseases, infectious ailments, and metabolic conditions. A key product is JUNMAIKANG, an Adalimumab injection utilized for autoimmune treatments. Mabwell also maintains a robust clinical pipeline, notably in oncology, where candidates 9MW2821 and 6MW3211 are advancing through Phase II studies, while 9MW2921, 9MW3811, and 7MW3711 are undergoing Phase I trials. Additionally, 8MW0511 has reached Phase III development, alongside 9MW0321. For autoimmune diseases, 9MW1911 and 9MW3811 are in their initial Phase I clinical trials. The company's metabolic product candidates include MAILISHU and 9MW3011. In ophthalmology, 9MW0813 and 9MW0211 are progressing through Phase III. Furthermore, 9MW1411 represents an infectious disease candidate in development.
- ISIN
- CNE100005RD2
- Founded
- 2017
- Listed since
- Jan 18, 2022
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $260.63 | -1.94% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $438.87 | -0.76% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.49 | -0.19% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.54 | -0.42% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $819.48 | -1.69% |
| argenx SEENXTBR: ARGX | $64.17B | €900.00 | +2.37% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $147.14 | -7.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.